---

Case Analysis: Shahjahan Sheikh, 44F — AKI on CKD + Pancytopenia

Summary of Key Data

---

Problem Interpretation

1. Evolution of Anemia — Critical Observation

• 2022: Hb 3.1, MCV 53.7 → Severely microcytic hypochromic with leptocytes, ferritin 7.9, iron 18, TIBC 344, TSAT ~5% → Pure iron deficiency anemia (IDA) at that time with normal renal function (Cr 0.86)
• 2026: Hb 6–7.5, MCV 88–89 → Normocytic normochromic + pancytopenia, Cr 4.64–10.14 → Anemia of CKD (EPO deficiency) ± evolving iron depletion

• Anisopoikilocytosis, elliptocytes, microcytes: mixed picture — possible residual iron deficiency + uremic marrow suppression
• Activated lymphocytes: consider reactive process (infection, AKI, autoimmune — though ANA negative x2)
• Thrombocytopenia with large platelets: suggests peripheral consumption/destruction OR marrow stress response

2. Pancytopenia in CKD — Differential

3. AKI on CKD

• Cr 10.14 on 27 Apr → improved to 4.64 (30 Apr) → 6.62 (01 May) — non-linear recovery, possible re-injury
• Urine ACR 2743 mg/g → severe proteinuria (A3 category)
• Urine R/M: blood + glucose + blood → hematuria + glucosuria
• HTN + proteinuria + AKI: raises concern for glomerulonephritis — ANA negative but does NOT rule out lupus nephritis (anti-dsDNA, C3, C4 not done), ANCA vasculitis, IgA nephropathy, diabetic nephropathy
• Ionized Ca 0.93 (low-normal), Ca 7.4 (low), Phosphorus 6.4 (high), PTH 1014 → CKD-MBD with severe 2° HPT

---

Further Investigations Required

For Pancytopenia Workup:

1. Reticulocyte count (current) — low = underproduction; elevated = hemolysis
2. LDH, indirect bilirubin, haptoglobin, DAT (direct antiglobulin test) — screen for hemolysis/TMA
3. Peripheral smear review for schistocytes — if present → TMA (HUS/TTP in AKI setting)
4. Serum ferritin, TSAT (current) — iron stores may now be replete post-transfusions
5. Vit B12, folate (current) — B12 was 218 in 2022 (low-normal)
6. Bone marrow aspiration + biopsy — critical given PTH 1014; expect marrow fibrosis from osteitis fibrosa; also rule out myelodysplasia/infiltrative disease
7. Serum protein electrophoresis (SPEP) + urine protein electrophoresis — rule out myeloma (proteinuria + pancytopenia + CKD + age 44F)
8. Flow cytometry of peripheral blood — if lymphoproliferative disorder suspected

For AKI on CKD / Nephritis Workup:

1. Anti-dsDNA, C3, C4, anti-Sm — lupus nephritis (ANA by IF was negative, but low-titre lupus can be ANA negative; dsDNA more specific)
2. ANCA (MPO + PR3) — ANCA-associated vasculitis
3. Anti-GBM antibody — Goodpasture (hematuria + proteinuria + AKI)
4. Complement C3, C4 — hypocomplementemic nephritis
5. Serum immunoglobulins, SPEP, BJP — IgA nephropathy, myeloma nephropathy
6. Renal biopsy — essential given urine ACR 2743, hematuria, AKI on CKD without clear diagnosis; will guide immunosuppressive therapy
7. Urine 24h protein or confirm ACR trend
8. Renal ultrasound — kidney size, echogenicity, rule out obstruction

For CKD-MBD:

1. Repeat PTH (intact iPTH), Vitamin D (25-OH), alkaline phosphatase
2. Bone X-ray (hands/skull) — subperiosteal resorption, "rugger jersey spine" if severe

For HTN + Hypothyroidism:

1. TSH, FT4 — is hypothyroidism contributing to anemia?
2. BP logs, ABPM — CKD hypertension management

---

Management Plan

A. AKI on CKD — Immediate

1. Identify and remove nephrotoxins — NSAIDs, contrast, nephrotoxic drugs; optimize BP
2. Fluid management — cautious IV fluids if pre-renal component; avoid fluid overload (Hb 7.0, risk of pulmonary edema)
3. Strict fluid balance, daily weights
4. Treat hypertension — target BP <130/80 mmHg in CKD with proteinuria; preferred agents: ACE inhibitor / ARB (antiproteinuric) — but hold temporarily if AKI is worsening (Cr rising); restart when Cr stable
5. Monitor renal function daily — the non-linear Cr trajectory (10.14→4.64→6.62) is concerning
6. Indications for urgent dialysis — if hyperkalemia K⁺ refractory, severe acidosis, uremic symptoms, fluid overload: K⁺ 3.96→3.65 (currently acceptable), plan renal replacement if no improvement

B. Anemia / Pancytopenia Management

1. Transfuse if Hb <7 g/dL (currently 7.0 — threshold met; symptoms guide decision)
   • Target Hb 8–10 g/dL per KDIGO 2025 anemia guideline
   • Caution: multiple prior transfusions → alloimmunization risk; use leucodepleted, CMV-safe blood
2. Iron status assessment first (ferritin + TSAT) before starting IV iron or ESA
   • If TSAT <20% and ferritin <500 → IV iron (ferric carboxymaltose or iron sucrose) — preferred over oral in CKD (hepcidin blocks oral absorption)
   • KDIGO 2025/2026: Consider IV iron even with ferritin up to 500 µg/L if TSAT <30%
3. ESA (Erythropoietin) — initiate once:
   • Iron replete (functional or absolute iron deficiency corrected)
   • AKI resolving (ESAs less effective in acute kidney injury)
   • Hb <10 g/dL, symptomatic
   • Dose: Epoetin alfa 50–100 IU/kg SC 3x/week OR Darbepoetin alfa weekly/fortnightly
   • Target Hb: 10–11.5 g/dL (do NOT target >13 g/dL — increased stroke/CV events)
4. Do NOT start ESA until bone marrow biopsy done (to exclude marrow fibrosis or malignancy causing hypo-response)
5. Folate supplementation (empiric, given prior B12 218)

C. CKD-MBD (PTH 1014, Ca 7.4 low, PO₄ 6.4 high)

1. Phosphate restriction — dietary phosphate 800–1000 mg/day
2. Phosphate binders — Calcium carbonate with meals (also treats hypocalcemia) OR Sevelamer (non-calcium-based, preferred if Ca is borderline/high or calcification present)
   • Avoid calcium binders if corrected Ca normalizes (risk hypercalcemia)
3. Active Vitamin D (Calcitriol / Alfacalcidol) — stimulates Ca absorption, suppresses PTH
   • Start only if Ca >8.4 and PO₄ controlled
4. Calcimimetics (Cinacalcet) — if PTH remains >9× upper limit despite above; not indicated yet as first step
5. Target PTH: KDIGO recommends maintaining iPTH in the range of 2–9× upper normal for CKD G3–G5 (not dialysis)
6. Severe 2° HPT (PTH 1014) can cause marrow fibrosis → this is a reversible cause of pancytopenia; aggressive management may partially restore marrow function

D. Hypothyroidism

• Confirm TSH control; hypothyroidism independently contributes to anemia (reduced EPO production, reduced RBC survival)
• Optimize levothyroxine dose

E. Hypertension

• Once AKI is stabilizing: RAAS blockade (ACEi/ARB) for antiproteinuric benefit
• ACR 2743 → this level of proteinuria mandates RAAS blockade when renal function permits

---

Red Flags Requiring Urgent Action

---

Priority Action List (Next 24–48 hours)

1. Peripheral smear review specifically for schistocytes (TMA screen)
2. Send: Reticulocyte count, LDH, haptoglobin, DAT, ferritin, TSAT, anti-dsDNA, C3/C4, ANCA, anti-GBM, SPEP, UPEP, TSH, Vit D, ALP, B12/folate
3. Renal ultrasound today
4. Daily RFT monitoring (Cr, K⁺, urea, bicarb)
5. Renal biopsy once AKI improving and Hb/platelets permit (Plt >80K needed; currently borderline)
6. Bone marrow biopsy to complete pancytopenia workup
7. Transfuse if Hb drops <7 or symptomatic; keep Plt >50K if biopsy planned
8. Phosphate binder + dietary phosphate restriction start now
9. Hold ACEi/ARB until AKI resolves, then restart for antiproteinuric effect
10. Nephrology + Hematology joint review

---

---

Case Analysis: Jaimin Chauhan, 22M — Pancytopenia + Macrocytic Anemia

Summary of Key Data

Note: Hb rising 5.3→6.6→8.3 after 1 PCV on 29 Apr — response to transfusion. Platelet trend: 97→75→25 — worsening thrombocytopenia despite improving Hb. This is clinically important.

---

⚠️ The Central Diagnostic Dilemma

---

Why is B12 Elevated? — Causes of Hypercobalaminemia

---

Peripheral Smear Interpretation — What the Findings Point To

---

Liver Findings — Clinically Significant

• AST 108 > ALT 52 (AST:ALT ratio >2) → suggestive of hepatocellular injury, possibly:
  • Infiltrative liver disease (lymphoma, leukemia)
  • Viral hepatitis (HBV, HCV — not yet checked)
  • Non-alcoholic steatohepatitis (fatty changes on USG)
• Total bilirubin 1.9 (indirect 1.22) — mild indirect hyperbilirubinemia → hemolytic component present (despite DCT/ICT negative — intravascular hemolysis or fragmentation)
• Hepatomegaly 15 cm + Splenomegaly 12 cm → hepatosplenomegaly — infiltrative process until proven otherwise

---

Iron Studies — Interpretation

• S. Iron 232 (normal–high), Ferritin 317 (elevated), TIBC 268 (low-normal)
• TSAT = (232/268) × 100 = ~87% — markedly elevated
• This pattern (high iron, high ferritin, low TIBC) suggests:
  • Inflammation/acute phase reaction (ferritin is acute phase reactant)
  • Hemolysis — iron release from destroyed RBCs
  • NOT iron deficiency — iron is not the driver of this anemia

---

Differential Diagnosis (Prioritized)

---

Further Investigations Required

URGENT (Before / At Same Time As Bone Marrow):

1. Serum Folate — B12 high but folate may be low; this is the only nutritional deficiency still possible
2. Serum Homocysteine + Methylmalonic acid (MMA) — elevated homocysteine in folate deficiency; elevated MMA only in B12 deficiency. Despite high B12, functional deficiency possible (rare)
3. LDH — critically important; markedly elevated in megaloblastic anemia, hemolysis, MDS, leukemia, HLH
4. Haptoglobin — if low, confirms hemolysis (complement to indirect bilirubin 1.22 already elevated)
5. Peripheral blood for blasts — flow cytometry / manual differential for blast % (not mentioned in reports)
6. JAK2 V617F mutation — essential for PMF/PV/ET; present in ~50–60% PMF
7. BCR-ABL — rule out CML (can cause marrow fibrosis variant)
8. Calreticulin (CALR) and MPL mutations — JAK2-negative PMF
9. Viral serology: HBsAg, Anti-HCV, EBV VCA IgM, CMV IgM — hepatosplenomegaly + pancytopenia in young male
10. Dengue NS1 negative (done) — good
11. HIV serology
12. Serum ferritin repeat (already 317) — if >500, HLH criterion met (diagnostic threshold for HLH in adults is ferritin ≥500, diagnostic strongly suggests >10,000)
13. HLH workup: NK cell activity, sCD25 (soluble IL-2 receptor), fasting triglycerides, fibrinogen
14. Peripheral blood smear review for blasts (by hematologist)
15. Urine for hemosiderin — if PNH suspected (young male, pancytopenia, hemolysis)
16. Flow cytometry for PNH clone (CD55/CD59)

Imaging:

1. CT Abdomen + Pelvis with contrast — better characterize hepatosplenomegaly, lymphadenopathy, portal hypertension
2. Chest X-ray / CT chest — mediastinal lymphadenopathy (lymphoma)

---

Bone Marrow Biopsy — Planning and Expectations

• Platelet count 25,000 → bleeding risk HIGH
• Transfuse single donor platelets (SDP) to bring Plt >50,000 before procedure
• Consider fresh frozen plasma if coagulopathy (PT-INR 1.21 — mildly prolonged; acceptable)
• Perform at iliac crest under aseptic technique

1. Aspirate + trephine biopsy (both mandatory)
2. Cellularity — hypercellular (MDS, megaloblastic), hypocellular (aplastic), normal
3. Reticulin staining — if grade 2–3 fibrosis → myelofibrosis confirmed
4. Iron staining (Prussian blue) — ring sideroblasts (MDS-RS)
5. Morphology: M:E ratio, blast %, dysplasia in 3 lineages
6. Immunohistochemistry panel: CD34, CD117, MPO, TdT
7. Cytogenetics / karyotype (conventional)
8. FISH panel: del(5q), del(7q), del(20q), +8 — common MDS cytogenetics
9. Molecular panel: JAK2, CALR, MPL, TP53, SF3B1, ASXL1

---

Management Plan

A. Immediate (Today)

1. STOP empirical B12 injections — B12 is 1562, this is elevated not deficient. Injecting B12 in a patient with possible myeloproliferative neoplasm or liver disease that is already releasing B12 is not beneficial and confounds future testing.
2. Platelet transfusion — Plt 25,000 is critically low; threshold for spontaneous bleeding; transfuse SDP, target >50K (>80K if planning biopsy)
3. Monitor for bleeding — epistaxis, gum bleed, petechiae, fundal hemorrhage
4. Hold any antiplatelet/anticoagulant drugs (none mentioned, but confirm)
5. Ophthalmology review — fundus exam for hemorrhagic retinopathy (Plt 25K)

B. Nutritional

1. Check and treat folate deficiency if serum folate low — Folic acid 5 mg/day oral (safe in all diagnoses, will not confound BMB)
2. Treat Vitamin D deficiency — Cholecalciferol 60,000 IU weekly × 8–12 weeks, then maintenance 1,000–2,000 IU/day; monitor 25-OH Vit D at 3 months

C. Once Bone Marrow Results Available

D. Liver Disease Management

1. Hepatology referral — hepatomegaly + AST:ALT >2 in 22M needs investigation
2. Viral hepatitis serology (HBsAg, anti-HCV) — treat if positive; HBV can cause aplastic anemia
3. Alcohol history — zero addiction reported, but confirm; fatty liver at 22y needs explanation
4. Avoid hepatotoxic drugs

---

⚠️ Key Alerts

---

One-Line Summary for Referring Team

22M with macrocytic pancytopenia, splenomegaly, hepatomegaly, teardrop cells, low reticulocyte count, elevated B12 (1562 — likely from hepatocellular leak or marrow disease, NOT deficiency) — pattern most consistent with primary myelofibrosis or myeloid neoplasm with marrow infiltration; MDS and HLH also in differential; bone marrow biopsy with full molecular panel required; empirical B12 therapy should be stopped; platelet transfusion required before biopsy.